The peptide reclassification, tracked — in one place.

Five days out, FDA has published nothing. We checked the agency's advisory-committee page for this meeting again this morning. It is still stamped "content current as of 06/29/2026" — the eight pre-meeting briefing documents are posted, but there are no official minutes, no transcript, and no archived webcast. That matters for one specific reason: the Epitalon tally discrepancy we flagged yesterday can only be settled against the official record, so that footnote stays up until FDA posts. We will check weekly and date the correction when it lands. Separately, we have confirmed the shape of the second PCAC meeting: expected before the end of February 2027, covering GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and PEG-MGF. Four of those five had previously been in a withdrawn / no-active-review state. FDA has not posted the date or opened the comment docket. Where we stand on each — including the two we would decline regardless of the vote — is in the refreshed peptide roadmap.

Vote counts refined, and one correction. Our first pass recorded the four Day-1 substances as a single favorable bloc. That was imprecise: MOTS-c did not carry the same margin as the other three. BPC-157, KPV, and TB-500 each passed 8–6 with one abstention; MOTS-c passed 7–5 with two abstentions — a narrower result, and worth stating plainly because MOTS-c is a molecule we actually use. The table above now carries the per-substance counts. We have also flagged a live discrepancy in public reporting of the Epitalon tally (7–4–1 in some accounts, 7–5–1 in others) rather than picking one silently; that line will be reconciled against FDA's official minutes when they post. Added national coverage citations to the post-vote read, along with a note on the panel's composition — a majority of yes-voting members have reported ties to the peptide industry, which is a reason to treat a favorable vote as a regulatory signal rather than as evidence of efficacy.

Final tallies confirmed across both sessions. The committee recommended adding six of the seven peptides to the 503A bulks list: BPC-157, KPV, TB-500 (Jul 23, 8–6–1 each), MOTS-c (Jul 23, 7–5–2), Semax (8–5–1) and Epitalon (7–4–1) on Jul 24. The lone rejection was Emideltide (DSIP), voted down narrowly 6–7–1. This is a real break from FDA staff, who had recommended against all seven in their briefing documents. What it means for you: nothing changes on the shelf today. A recommendation is not a rule — FDA still has to accept the input, publish a proposed rule, run a second comment period, and issue a final rule. That path runs 6–12+ months at minimum. Our posture is unchanged: prescribe inside named indications, source through licensed 503A pharmacies, disclose the uncertainty in writing.

Day two. The committee recommended Semax (8–5–1) and Epitalon (7–4–1) for addition, and declined Emideltide/DSIP (6–7–1) — the only "no" of the meeting. Combined with Thursday's favorable votes on BPC-157, KPV, TB-500 and MOTS-c, that is a 6-of-7 record. The results table above now reflects the recorded outcomes.

Day one. The panel broke from FDA staff and voted 8–6–1 to recommend adding BPC-157, KPV, and TB-500 to the 503A list, and recommended MOTS-c as well on a narrower 7–5–2. These are advisory recommendations, not rules — see the standing explainer above. Patient posture unchanged.

Meeting eve. The public comment docket (FDA-2025-N-6895 at regulations.gov) closes tonight at 11:59 p.m. ET — the last moment to be on record before the committee meets. Our physician comment was filed back in May, so we are already in the record. The FDA's meeting page still has not posted the live-webcast link (the “two business days before” target has passed); we’ll add it here the moment it appears, and the agency may only post it day-of. A pre-staged day-of results table is now live on this page and will fill in as each substance is voted Thursday and Friday. Patient posture is unchanged: nothing on the Limitless menu changes on the strength of a committee vote.

Ten days out. The public comment docket (FDA-2025-N-6895 at regulations.gov) closed on July 9 — comments filed by that date reach the committee in advance of the vote — and the full docket closes July 22, the day before the meeting. FDA's own scientific briefing materials read negative on all seven peptides going in, which is exactly why the "recommendation is not a rule" framing above matters: even a favorable committee vote would still require FDA to publish a proposed rule, run a second comment period, and issue a final rule — a 1+ year path — before any peptide's durable 503A status changes. Nothing on the Limitless menu changes on the day of the vote. We will update this tracker and the patient FAQ within 48 hours of any final FDA action.

Added a plain-language explainer above on what a "yes" vote does and does not mean — because the vote-day coverage will blur the line. PCAC recommends; FDA then has to publish a proposed rule, run a second comment period, and issue a final rule before any peptide's durable 503A status actually changes. Nothing about your protocol changes on the day of the vote. Meeting is now 25 days out; comment window still open through July 22.

Re-verified the full agenda against the FDA's Federal Register notice and advisory-committee calendar (docket FDA-2025-N-6895): seven peptides across two days are confirmed — day one (July 23): BPC-157, KPV, TB-500, MOTS-c; day two (July 24): Emideltide (DSIP), Semax, Epitalon. The earlier vendor-blog chatter that floated a different slate is now superseded by the official posting. Comment window is open through July 22; comments filed by July 9 reach the committee before the vote. Posture unchanged — the meeting is now 30 days out.

Folded the newest skeptic reporting — STAT ("BPC-157: big claims and scant evidence," Feb 3) and The Conversation ("the peptide problem") — into our hype-vs-evidence brief. Our posture is unchanged: prescribe inside named indications, source through 503A only, disclose the uncertainty. Launched this tracker to keep the whole story in one place ahead of the July meeting.

Confirmed the public FDA agenda detail that each day-one peptide (BPC-157, KPV, TB-500, MOTS-c) is nominated as two substances — free base and acetate — which the committee can vote on separately. Updated the meeting explainer and our filed-comment page accordingly.

Filed our formal public comment with the FDA ahead of the vote — a physician's case to include BPC-157, TB-500, and MOTS-c on the 503A bulks list, with per-lot certificate-of-analysis, stability, and written informed-consent conditions attached. Full text published.

Removed CJC-1295 from the standing menu after verifying it is not currently legal for human compounding and is not on the July docket. Tesamorelin remains the GH-axis lead; sermorelin is the alternative; ipamorelin is conditional on partner-pharmacy formulary.

FDA reclassification restored legal compounding of the affected peptides through licensed 503A pharmacies — the event that set the July 23–24 PCAC review in motion.